Markets Soft as Earnings Season Grinds On
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
RBC's Yee Sees Interesting Buying Opportunities in Biotech Pullback (BIIB) (BMRN) (ESPR) (GILD)
May 4, 2015 10:21 AM EDTLast week was tough on biotech investors, with broad weakness in the space. The decline was similar to March's pullback, which was short-lived. In the view of analyst Michael J. Yee of RBC, investors are used to corrections, and the drop creates interesting buying opportunities.
Long ideas mentioned by Yee include Biogen (NASDAQ: BIIB), Vertex Pharma (NASDAQ: VRTX), BioMarin Pharma... More
